| Schedule of Antidilutive Earnings Per Share |
Schedule of Antidilutive Earnings Per Share
| | |
2026 | | |
2025 | |
| | |
Three Months Ended March 31, | |
| | |
2026 | | |
2025 | |
| Restricted stock units | |
| 2,099,586 | | |
| 1,912,895 | |
| Warrants for Common Stock | |
| 12,364,114 | | |
| 12,364,114 | |
| Convertible debt | |
| - | | |
| 5,468,831 | |
| Deferred underwriter fees | |
| - | | |
| 3,174,999 | |
| Loan extensions | |
| 330,000 | | |
| 3,274,182 | |
| Total common stock equivalents | |
| 14,793,700 | | |
| 26,195,021 | |
|
As
a result of the Company reporting net loss attributable to common stockholders for all periods presented herein, the following common
stock equivalents were excluded from the computation of diluted net loss per common share for the years ended December 31, 2025 and 2024
because including them would have been antidilutive (in thousands):
Schedule of Antidilutive Earnings Per Share
| | |
2025 | | |
2024 | |
| | |
Year Ended December 31, | |
| | |
2025 | | |
2024 | |
| Restricted stock units | |
| 3,211,252 | | |
| 1,625,404 | |
| Convertible debt | |
| - | | |
| 8,549,417 | |
| Warrants for common stock | |
| 12,314,114 | | |
| 12,364,114 | |
| Deferred underwriter fees | |
| - | | |
| 3,174,999 | |
| Loan extensions | |
| 330,000 | | |
| 3,274,182 | |
| Total common stock equivalents | |
| 15,855,366 | | |
| 28,988,116 | |
|